Supratentorial Primitive Neuroectodermal Tumors (sPNET): Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Supratentorial primitive neuroectodermal tumors (sPNET) are a group of rare, highly malignant embryonal brain tumors arising in the cerebral hemispheres above the tentorium cerebelli. In the WHO 2021 Classification of Tumors of the Central Nervous System, the term 'sPNET' as a unified category has largely been superseded — these tumors are now more precisely classified by molecular and genetic characteristics into distinct entities including embryonal tumor with multilayered rosettes (ETMR, characterized by C19MC amplification), CNS neuroblastoma (FOXR2-activated), CNS ganglioneuroblastoma, and CNS NEC (not elsewhere classified). They are distinguished from medulloblastoma (which arises in the posterior fossa/cerebellum). sPNETs predominantly affect infants and young children under 5 years, with a secondary peak in older children. They are highly aggressive, prone to leptomeningeal dissemination via CSF pathways at diagnosis (occurring in approximately 10–30% of cases), and carry a significantly worse prognosis than medulloblastoma, with 5-year overall survival rates of approximately 20–40% despite multimodal therapy.

The pathogenesis of sPNET involves complex genomic alterations during early brain development. Embryonal tumor with multilayered rosettes (ETMR) — the most distinctly characterized subtype — is defined by amplification of the C19MC (chromosome 19 microRNA cluster) region and overexpression of LIN28A, which can be used as an immunohistochemical diagnostic marker. CNS neuroblastoma is characterized by FOXR2 gene activation. Other molecular alterations include TP53 mutations, MYCN amplification, and chromatin remodeling gene mutations. There are no established environmental or lifestyle risk factors for sPNET. Germline TP53 mutations (Li-Fraumeni syndrome) are found in a small subset of children with sPNET and other pediatric cancers, and genetic counseling is recommended in this setting. Prior cranial radiation therapy to the head (e.g., for infant leukemia) is a rare but recognized risk factor for secondary brain tumors including embryonal tumors. Overall, most sPNET cases are sporadic with no identifiable predisposing factor.

Symptoms of sPNET reflect increased intracranial pressure and local mass effect from rapidly growing supratentorial hemispheric lesions. In infants, rapidly enlarging head circumference (macrocephaly), bulging fontanelle, irritability, vomiting, lethargy, and failure to thrive are the predominant presenting features. In older children, headaches — characteristically worse in the morning and associated with vomiting — are the most common presenting complaint, reflecting raised intracranial pressure. Focal neurological deficits corresponding to tumor location include hemiparesis, aphasia (dominant hemisphere), visual field defects, and behavioral or personality changes. New-onset seizures occur in a significant proportion. Diplopia from CN VI palsy indicates intracranial hypertension or brainstem involvement. Leptomeningeal dissemination at diagnosis may cause back pain, spinal nerve root signs, or symptoms of hydrocephalus from CSF obstruction. The rapid rate of growth of these tumors means clinical progression can occur over days to weeks, and prompt evaluation is critical.

MRI brain with gadolinium contrast is the primary diagnostic modality. sPNET typically appears as a large, heterogeneous supratentorial mass with areas of necrosis, cyst formation, calcification, and heterogeneous enhancement. DWI demonstrates restricted diffusion reflecting high tumor cellularity (low ADC values). MR spectroscopy shows elevated choline and reduced NAA ratios. MRI spine with gadolinium contrast is mandatory at diagnosis to evaluate leptomeningeal dissemination (drop metastases, nodular enhancement). CSF analysis — obtained by lumbar puncture after documentation of absent or managed raised ICP — assesses cytology for tumor cells. Staging follows the Chang and COG staging systems, with M0 (no metastasis) to M4 (extraneural metastasis). Neurosurgical resection provides diagnostic tissue; histopathology and molecular profiling (C19MC FISH, LIN28A IHC, RNA sequencing panel) are essential for accurate WHO 2021 classification. MYCN amplification and TP53 status are assessed as prognostic markers. Baseline ophthalmology, endocrinology, and neuropsychological assessments establish pre-treatment function.

Treatment requires a multimodal approach at specialized pediatric cancer centers. Maximal safe surgical resection is the initial goal — complete or near-complete (>90%) resection significantly improves progression-free survival and overall survival compared to subtotal resection. Gross total resection reduces residual tumor burden for subsequent therapy. Post-operative MRI within 48–72 hours confirms extent of resection. Craniospinal irradiation (CSI) at 36 Gy (standard risk) or 36 Gy (high risk, metastatic) to the entire craniospinal axis with a boost to 54–55.8 Gy to the primary tumor bed is part of standard multimodal treatment in children over 3 years. Due to devastating neurocognitive and endocrine sequelae, craniospinal radiation is avoided in children under 3 years (infant protocols) and replaced by intensive chemotherapy — typically 'head start' regimens with carboplatin, etoposide, vincristine, and cyclophosphamide, followed by high-dose chemotherapy with autologous stem cell rescue (HDC-ASCR) to defer or avoid radiation. Maintenance chemotherapy with CCNU, vincristine, and cisplatin following radiation is standard for older children (Children's Oncology Group protocols). The prognosis for ETMR (C19MC-amplified) remains particularly poor despite intensive therapy, and novel targeted approaches including FGFR inhibitors and EZH2 inhibitors are under investigation in clinical trials.

The prognosis for supratentorial primitive neuroectodermal tumors (sPNET) is significantly worse than for medulloblastoma, reflecting the aggressive biology, frequent leptomeningeal dissemination, and limited treatment response of these rare tumors. Five-year overall survival across all sPNET entities ranges from approximately 20–40% with current multimodal therapy. Embryonal tumor with multilayered rosettes (ETMR), defined by C19MC amplification, carries a particularly dismal prognosis with 5-year survival below 20% and median overall survival under 18 months despite intensive multimodal therapy. Infants under 3 years of age have especially poor outcomes because craniospinal irradiation must be deferred or avoided to protect the developing brain, and chemotherapy-alone approaches — including high-dose chemotherapy with autologous stem cell rescue — achieve limited durable tumor control. Extent of surgical resection is among the most important prognostic factors — complete or near-complete (>90%) resection significantly improves survival compared to subtotal resection. Metastatic disease at diagnosis (M1–M4 by Chang staging) confers substantially worse prognosis than non-metastatic (M0) disease. The molecular subgroup — particularly C19MC amplification in ETMR and FOXR2 activation in CNS neuroblastoma — is increasingly recognized as a dominant prognostic driver. Children who receive craniospinal irradiation face significant late effects including neurocognitive impairment, growth hormone deficiency, hypothyroidism, premature puberty, cisplatin-induced hearing loss, and risk of secondary malignancies, which represent a major burden in long-term survivors. Enrollment in collaborative international clinical trials testing novel molecularly targeted agents represents the most important avenue for improving these poor outcomes.

There are no established preventive measures for sPNET given its sporadic occurrence in most cases. Genetic counseling and Li-Fraumeni syndrome testing (TP53 germline sequencing) should be offered when clinical features suggest hereditary predisposition (multiple childhood cancers, family history of Li-Fraumeni tumors). Long-term survivorship care addresses the significant late effects of treatment — particularly craniospinal irradiation — which include intellectual and neurocognitive impairment, endocrine dysfunction (growth hormone deficiency, hypothyroidism, pubertal delay, adrenal insufficiency), hearing loss (from cisplatin ototoxicity), secondary brain tumors, and musculoskeletal effects. Neuropsychological assessment, endocrine follow-up, audiological testing, and GH replacement for deficient patients are standard components of survivor care. Participation in long-term follow-up programs through specialized pediatric oncology centers is essential. Transition to adult survivorship care services at age 18 requires comprehensive handover documentation.

Parents of infants and young children should seek immediate emergency evaluation for rapidly enlarging head, bulging fontanelle, persistent vomiting, extreme irritability, or new-onset seizures — these may indicate raised intracranial pressure from a brain tumor. Older children with persistent morning headaches associated with vomiting — a pattern inconsistent with migraine — need urgent neurological assessment and brain MRI. New focal neurological signs in a child (weakness of one side, vision changes, speech difficulty) require emergency evaluation. Any child or adolescent with an unexplained seizure should have a brain MRI as part of the initial workup. Papilledema on fundoscopy (swelling of the optic disc from raised ICP) is a neurosurgical emergency. When sPNET is diagnosed, referral to a specialist pediatric neuro-oncology center with experience in embryonal brain tumors is mandatory — treatment should not be initiated at centers without this expertise.